Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Positive first-in-human results of Novartis' ATF-936 for the treatment of osteoporosis

Oct. 2, 2008

Indevus initiates phase III octreotide implant trial in patients with acromegaly

Oct. 1, 2008

Aclasta approved in Europe for osteoporosis in men with high risk of fractures

Oct. 1, 2008

OCT-1547, a novel small-molecule candidate for osteoporosis

Oct. 1, 2008

Takeda submits NDA in Japan for Actos orally disintegrating tablets

Sep. 30, 2008

Takeda submits NDA for alogliptin in Japan

Sep. 30, 2008

Savient provides business development update for pegloticase

Sep. 30, 2008

Takeda submits NDA to the FDA for alogliptin/Actos tablet for type 2 diabetes

Sep. 30, 2008

Merck & Co. and Japan Tobacco enter licensing agreement for JTT-305 for osteoporosis

Sep. 30, 2008

Concert commences phase I CTP-347 trial in healthy volunteers

Sep. 29, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 18, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...